Citius Oncology Plunges 10.34% Amid LYMPHIR Launch Preparations

Citius Oncology's stock price plummeted by 10.34% in pre-market trading on June 18, 2025, marking a significant downturn for the biotechnology company.

Citius Oncology has completed the commercial-scale manufacturing of LYMPHIR, an FDA-approved immunotherapy for treating adults with relapsed or refractory cancer. The company now holds packaged and labeled inventory at a leading global Contract Development and Manufacturing Organization (CDMO), signaling its readiness for the commercial launch.

The commercial launch of LYMPHIR is anticipated in the second half of 2025. This immunotherapy targets the IL-2 receptor, offering a novel approach to cancer treatment. The company's preparations for the launch include entering into a distribution services agreement with Cardinal Health, further solidifying its supply chain and market readiness.